Neoplasm Metastasis
Conditions
Interventions
investigational material(s)
Generic name etc : LY2940680
INN of investigational material :
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational materia
Sponsors
Eli Lilly Japan K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Have histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or metastatic. The participants must be an appropriate candidate for the experimental therapy after available standard therapies have failed to provide clinical benefit for their disease - Have the presence of measurable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors Guideline Version 1.1 - Have adequate organ function - Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy for at least 3 weeks prior to study enrollment, and have recovered from the acute effects of any such therapy - Males must agree to use medically approved barrier contraceptive precautions during the study and for 6 months following the last dose of study drug - Females with child bearing potential must agree to use medically approved contraceptive precautions during the study and for 6 months following the last dose of study drug; have had a negative serum pregnancy test equal to or less than 7 days before the first dose of study drug - Have an estimated life expectancy which will permit the participant to complete 2 cycles of treatment - Are able to swallow tablets
Exclusion criteria
Exclusion criteria:
Outcome results
None listed